Eli Lilly

News

Lilly swoops on Morphic to claim IBD drug candidate

Eli Lilly has bolstered its inflammatory bowel disease (IBD) pipeline with a $3.2 billion bid to acquire Morphic and its mid-stage oral integrin therapy MORF-057.

News

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch it at a cost it claims could deliver savings compared to a rival therapy fro

News

Radionetics Oncology's chief executive Paul Grayson

Lilly builds in radiopharma with $140m Radionetics deal

Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outr

News

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busti

News

Scotland first UK nation to clear Mounjaro use for obesity

Scotland has become the first country in the UK to back NHS use of Eli Lilly’s obesity therapy Mounjaro, clearing it to assist weight management in eligible patients.

News

Boehringer, Lilly face off in MASH at EASL

Drugs from Eli Lilly and Boehringer Ingelheim grabbed the spotlight at the EASL congress on liver diseases, both showing promising results in metabolic dysfunction-associa

Lilly swoops on Morphic to claim IBD drug candidate

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

Lilly builds in radiopharma with $140m Radionetics deal

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

Scotland first UK nation to clear Mounjaro use for obesity

Boehringer, Lilly face off in MASH at EASL

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Eli Lilly

Editor's Picks